ClinicalTrials.gg
CompletedNCT00241488Updated Feb 7, 2008

DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia

A Phase 3 interventional study of Rosuvastatin in Hypercholesterolemia, sponsored by AstraZeneca. Completed at 34 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-02-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,362
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Planned enrollment
13th of 57
1,362 · median 203
Started
2003
with 6 others
Phase 3
33 of 59
none open now
Registered
6th of 59
by date
Lead sponsor
25 of 59
AstraZeneca

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 13th largest by planned enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2003, is one of 33 in phase 3, and was the 6th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visit 1:

    1. Written to participate in the trial (Appendix B)
    2. Male or female subjects, age > 18 years
    3. Primary hypercholesterolaemia with CV risk > 20%/10yrs, type 2 diabetes, a history of CHD or other established atherosclerotic disease (definition given in Appendix L).
    4. Subjects may be lipid-lowering therapy-naïve, but have completed 6-weeks dietary counselling before this visit OR Subjects may be treated with the 'start' dose of other lipid lowering therapy, which is ineffective, ie. The subject has not met LDL-C treatment goals.
    5. Subjects willing to follow all study procedures including attendance at clinics for scheduled study visits, fasting prior to blood draws and compliance with study treatment regimen

      Visit 2:

    6. Subjects switched from start dose of a lipid lowering therapy (commonly accepted start dose) will have fasting LDL-C levels > 3.1 mmol (120 mg/dl)
    7. Newly treated subjects, after a six-weeks dietary counselling, will have fasting LDL-C levels > 3.5 mmol/L (135 mg/dL)
    8. Fasting triglycerides £ 4.52 mmol/L (400 mg/dL)
    9. Switched patients must stop current lipid lowering treatment at randomisation (Visit 2)

Exclusion criteria

Exclusion Criteria:

  1. Known heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia)
  2. Documented secondary hypercholesterolaemia of any cause other than named in inclusion criteria 3
  3. History of serious adverse effect or reactions to other HMG-CoA reductase inhibitors, in particular any history of myopathy
  4. Unstable angina within three months prior to inclusion in the study
  5. Active liver disease or hepatic dysfunction as defined by elevations of or ALT ³ 1.5 times the . In this case, a second determination of hepatic tests will be performed after one week. If the dysfunction is confirmed, the subject must not be included in the study
  6. Known uncontrolled diabetes
  7. Uncontrolled hypertension defined as either resting diastolic blood pressure of > 95mmHg or resting systolic blood pressure of > 200 mmHg
  8. Unexplained serum CK > 3 times ULN (eg not due to recent trauma, intramuscular injections, heavy exercise etc)
  9. Serum creatinine > 220 µmol/L (2.5mg/dL)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,362 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy

Secondary outcomes

  1. Secondary objectives of the study are:

  2. 1. To compare the efficacy of rosuvastatin 10 mg with atorvastatin 10mg by assessment of the percentage of subjects who reach EAS TC treatment goals after 12 weeks of therapy.

  3. 2. Percentage change in LDL-C, TC, HDL-C and TG from pre-dose (week 0) and 12 weeks which will be performed separately for the switched and the naïve patients.

  4. 3. To compare rosuvastatin 10 mg with atorvastatin 10 mg after 12 weeks of treatment with respect to the incidence and severity of adverse events and abnormal laboratory values.

07

Study locations

34 sites
  • Beijing, China
  • Ching Qing, China
  • Guang Zhou, China
  • Harbin, China
  • Ji Nan, China
  • Nanjing, China
  • Shanghai, China
  • Shenyang, China
  • Wu Han, China
  • New Territories, Hong Kong
  • Busan, Korea, Republic of
  • Cheonan-si, Korea, Republic of
  • Daegu, Korea, Republic of
  • Ilsan, Korea, Republic of
  • Incheon-Si, Korea, Republic of
  • Kwangju, Korea, Republic of
  • Pusan, Korea, Republic of
  • Pyungchon Kyonggi, Korea, Republic of
  • Seoul, Korea, Republic of
  • Suwon, Korea, Republic of
  • Wonju, Korea, Republic of
  • Kuching, Sarawak, Malaysia
  • Bandar Sunway, Selangor, Malaysia
  • Shah Alam, Selangor, Malaysia
  • Kuala Lumpur, Malaysia
  • Penang, Malaysia
  • Petaling Jaya, Malaysia
  • Seberang Perai Utara, Malaysia
  • Chunghua City, Taiwan
  • Kaohsiung, Taiwan
  • Taichung City, Taiwan
  • Taipei, Taiwan
  • Tao-Yuan, Taiwan
  • Bangkok, Thailand
08

References and documents

Publications

  • Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin. 2007 Dec;23(12):3055-68. doi: 10.1185/030079907x242809. PubMed 18196620 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003, a primary completion of Dec 2005 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2005
First posted
Oct 19, 2005
Start
Jun 2003
Primary completionActual
Dec 2005
CompletionActual
Feb 2007
Last update
Feb 7, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00241488
Lead sponsor
AstraZeneca
First posted
Oct 19, 2005
Start date
Jun 2003
Primary completion
Dec 2005
Completion
Feb 2007
Last update
Feb 7, 2008

Study contacts

AstraZeneca China Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion